Inmunotek

Inmunotek is a privately held, revenue-generating biopharmaceutical company with a 30+ year legacy, founded on clinical laboratory roots. It has established itself as a commercial leader in allergy immunotherapy, with a broad portfolio of approved products and a growing pipeline that includes a notable bacterial vaccine candidate for recurrent urinary tract infections. The company is recognized for its innovation, receiving Spain's National Innovation Award, and operates with a fully integrated model from R&D to global commercialization, supported by a team of over 300 employees.

Proprietary allergen and bacterial antigen formulation platform utilizing glutaraldehyde cross-linking to modify structure and immunogenicity. Capabilities in sublingual and subcutaneous immunotherapy, and in-house production of biological raw materials (bacteria, fungi, mites).

Inmunotek competes with large pharma (e.g., ALK, Stallergenes Greer) in the allergy immunotherapy space. For Uromune®, it faces competition from other vaccine developers and antibiotic prophylaxis. Its integrated manufacturing and focus on formulation science are key differentiators.